Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) reported second-quarter net product revenue of $200.5 million, representing 16% year-over-year growth, according to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE